Nonpeptide αvβ3 Antagonists. 8. In Vitro and in Vivo Evaluation of a Potent αvβ3 Antagonist for the Prevention and Treatment of Osteoporosis

Journal of Medicinal Chemistry

Volumn 46, Issue 22, 2003, Pages 4790-4798

  Hutchinson, John H ^a   Halczenko, Wasyl ^a   Brashear, Karen M ^a   Breslin, Michael J ^a   Coleman, Paul J ^a   Duong, Le T ^a   Fernandez Metzler, Carmen ^a   Gentile, Michael A ^a   Fisher, John E ^a   Hartman, George D ^a   Huff, Joel R ^a   Kimmel, Donald B ^a   Leu, Chih Tai ^a   Meissner, Robert S ^a   Merkle, Kara ^a   Nagy, Rose ^a   Pennypacker, Brenda ^a   Perkins, James J ^a   Prueksaritanont, Thomayant ^a   Rodan, Gideon A ^a   Varga, Sandor L ^a   Wesolowski, Greg A ^a   Zartman, Amy E ^a   Rodan, Sevgi B ^a   Duggan, Mark E ^a   more..

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(6 METHOXYPYRIDIN 3 YL) 3 [2 OXO 3 [3 (5,6,7,8 TETRAHYDRO[1,8]NAPHTHYRIDIN 2 YL)PROPYL]IMIDAZOLIDIN 1 YL]PROPIONIC ACID; ALENDRONIC ACID; ALPHA5 INTEGRIN; BETA3 INTEGRIN; DRUG METABOLITE; IMIDAZOLIDINE DERIVATIVE; INTEGRIN RECEPTOR; OXIDIZING AGENT; RECEPTOR BLOCKING AGENT; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BONE TURNOVER; CONTROLLED STUDY; DOG; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG METABOLISM; DRUG OXIDATION; DRUG POTENCY; DRUG SAFETY; DRUG SCREENING; DRUG SELECTIVITY; FEMALE; IC 50; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; OSTEOPOROSIS; RAT; RHESUS MONKEY;

EID: 0142060908     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm030306r     Document Type: Article

References (34)

1. Eastell, R. Treatment of Postmenopausal Osteoporosis. N. Engl. J. Med. 1998, 338, 736-746.
2. Sato, M.; Grese, T. A.; Dodge, J. A.; Bryant, H. U.; Turner, C. H. Emerging Therapies for the Prevention or Treatment of Postmenopausal Osteoporosis. J. Med. Chem. 1999, 42, 1-24.
3. Goltzman, D. Discoveries, Drugs and Skeletal Disorders. Nature Rev. Drug Disc. 2002, 1, 784-796.
4. Rodan, S. B.; Rodan, G. A. Integrin Function in Osteoclasts. J. Endocrinology 1997, 154, S47-S56.
5. Vaananen, H. K.; Liu, Y.-K.; Lehenkari, P.; Uemara, T. How do Osteoclasts Resorb Bone? Mater. Sci. Eng. C 1998, 6, 205-209.
6. Shankar, G.; Horton, M. Osteoclast Integrins: Adhesion and Signaling. Adv. Organ Biol. 1998, 5B, 315-329.
7. Fisher, J. E.; Caulfield, M. P.; Sato, M.; Quartuccio, H. A.; Gould, R. J.; Garsky, V. M.; Rodan, G. A.; Rosenblatt, M. Inhibition of Osteoclastic Bone Resorption in Vivo by Echistatin, an "Arginyl-Glycyl-Aspartyl" (RGD)-Containing Protein. Endocrinology 1993, 132, 1411-1413.
8. Yamamoto, M.; Fisher, J. E.; Gentile, M.; Seedor, J. G.; Leu, C.-T.; Rodan, S. B.; Rodan, G. A. The Integrin Ligand Echistatin Prevents Bone Loss in Ovariectomized Mice and Rats. Endocrinology 1998, 139, 1411.
9. 3 Integrin Inhibits Osteoclast-Mediated Bone Resorption in the Thyroparathyroidectomized Rat. Endocrinology 1996, 137, 918.
10. 3 Integrin Inhibits Bone Resorption In Vitro and Prevents Osteoporosis In Vivo. J. Clin. Invest. 1997, 99, 2284-2292.
11. Lark, M. W.; Stroup, G. B.; Hwang, S. M.; James, I. E.; Rieman, D. J.; Drake, F. H.; Bradbeer, J. N.; Mathur, A.; Erhard, K. F.; Newlander, K. A.; Ross, S. T.; Salyers, K. L.; Smith, B. R.; Miller, W. H.; Huffman, W. F.; Gowen, M. Design and Characterization of Orally Active Arg-Gly-Asp Peptidomimetic Vitronectin Receptor Antagonist SB 265123 for Prevention of Bone Loss in Osteoporosis. J. Pharmacol. Exper. 1999, 291, 612-617.
12. Miller, W. H.; Alberts, D. P.; Bhatnagar, P. K.; Bondinell, W. E.; Callahan, J. F.; Calvo, R. R.; Cousins, R. D.; Erhard, K. F.; Heerding, D. A.; Keenan, R. M.; Kwon, C.; Manley, P. J.; Newlander, K. A.; Ross, S. T.; Samanen, J. M.; Uzinskas, I. N.; Venslavsky, J. W.; Yuan, C. C.-K.; Haltiwanger, R. C.; Gowen, M.; Hwang, S.-W.; James, I. E.; Lark, M. W.; Rieman, D. J.; Stroup, G. B.; Azzarano, L. M.; Salyers, K. L.; Smith, B. R.; Ward, K. W.; Johanson, K. O. ; Huffman, W. F. Discovery of Orally Active Nonpeptide Vitronectin Receptor Antagonists Based on a 2-Benzazepine Gly-Asp Mimetic. J. Med. Chem. 2000, 43, 22-26.
13. Hoffman, S. J.; Vasko-Moser, J.; Miller, W. H.; Lark, M. W.; Gowen, M.; Stroup, G. Rapid Inhibition of Thyroxine-Induced Bone Resorption in the Rat by an Orally Active Vitronectin Receptor Antagonist. J. Pharm. Exp. 2002, 302, 205.
14. 3Integrin Antagonists as Inhibitors of Bone Resorption. Exp. Opin. Invest. Drugs 2000, 9, 1281-1291.
15. 3. Exp. Opin. Ther. Pat. 2000, 10, 1367-1385.
16. 3. Exp. Opin. Ther. Pat. 2002, 12, 1009-1021.
17. 3 Antagonists. Part 2: Constrained Glycyl Amides Derived from the RGD Tripeptide. Bioorg. Med. Chem. Lett. 2002, 12, 25-29.
18. 3 Antagonists. Part 4: Potent and Orally Bioavailable Chain-Shartened RGD Mimetics. Bioorg. Med. Chem. Lett. 2002, 12, 2463-2465.
19. 3 Antagonists. Presented at the American Chemical Society National Meeting, Boston, Aug 2002; Paper 222.
20. 3 Antagonist for the Prevention of Osteoporosis. Presented at the American Chemical Society National Meeting, Boston, Aug 2002; Paper 223.
21. Dhokte, U. P.; Rao, A. S. Synthesis of the Pheromones, (E)-3,7-Dimethyl-2,7-octadienyl Propionate, (E)-3,7-Dimethyl-2-octene-1,8-diol and Frontalin From a Common Intermediate. Synth. Commun. 1988, 18, 811-822.
22. Rivera, N. R.; Hsiao, Y.; McWilliams, C.; Cowen, J. A.; Armstrong, J.; Yasuda, N.; Hughes, D. L. Highly Efficient Synthesis of 2-Amino-3-pyridinecarboxaldehyde. Synth. Commun. 2001, 31, 1573-1579.
23. Davies, S. G.; Ichihara, O. Asymmetric Synthesis of R-β-Amino Butanoic Acid and S-β-Tyrosine: Homochiral Lithium Amide Equivalents for Michael Additions to α,β-Unsaturated Esters. Tetrahedron Asymmetry 1991, 2, 183-186.
24. 3 Antagonists. Part 3: Identification of Potent RGD Mimetics Incorporating Novel β-Amino Acids as Aspartic Acid Replacements. Bioorg. Med. Chem. Lett. 2002, 12, 31-34.
25. log P: Measured from octanol, pH 7.4 buffer.
26. Protein binding: Human plasma binding measured in a high-throughput manner using ultrafiltration of diluted plasma in a pH 7.4 buffer. The analysis is conducted at room temperature, and solutions are analyzed by HPLC.
27. 3 Antagonist. J. Med. Chem. 2000, 43, 3736-3745.
28. 3 Antagonists Containing Containing a Pyridone or Pyrazinone Central Scaffold. Bioorg. Med. Chem. Lett. 2003, 13, 1809-1812.
29. 3 receptor was measured by inhibition of ADP-stimulated aggregation of human gel-filtered platelets, see: Hutchinson, J. H.; Cook, J. J.; Brashear, K. M.; Breslin, M. J. ; Glass, J. D.; Gould, R. J.; Halczenko, W.; Holahan, M. A.; Lynch, R. J.; Sitko, G. R.; Stranieri, M. T.; Hartman, G. D. NonPeptide Glycoprotein Iib/IIIa Antagonists. 11. Design and In Vivo Evaluation of 3,4-Dihydro-1(1H)-isoquinolinone-Based Antagonists and Ethyl Ester Prodrugs. J. Med. Chem. 1996, 39, 4583-4591.
30. Perin, D. D. Dissociation Constants of Organic Bases in Aqueous Solution, IUPAC: Oxford. U.K., 1965.
31. Kimmel, D. Animal Models for In Vivo Experimentation in Osteoporosis Research. In Osteoporosis; Marcus, R., Feldman, D., Kelsey, J., Eds.; Academic Press: San Diego, 1996; pp 671-690.
32. Russell, R. G. G. The Assessment of Bone Metabolism In Vivo Using Biochemical Approaches. Horm. Metab. Res. 1997, 29, 138-144.
33. Arison, B. H.; Cui, D.; Duggan M. E.; Halczenko, W.; Hutchinson, J. H.; Prueksaritanont, T.; Subramanian, R.; Fang, X. αv Integrin receptor antagonists. US Patent, US 6,426,353.
34. 125I]-L-775, 219. J. Labelled Compd. Radiopharm. 2001, 44, 55-59.